LEXX Lexaria Bioscience Corp.

CIK 0001348362 25 ready 8-Ks latest February 6, 2026, 6:59 PM ET RSS · JSON

Activity: NORMAL 0 filings / 30d vs 0 baseline

Ready 8-Ks 25

Latest filing February 6, 2026, 6:59 PM ET

Top materiality 0.75

Event mix other_material ×18 · leadership ×4 · other ×2

Sentiment 4 pos · 2 neg · 19 neu

Executive change recent →

SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for LEXX

Highest-materiality recent filing

Lexaria closes $4M registered direct offering of 2.67M shares at $1.50 with warrants at $1.37

September 29, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 8.01 item 9.01

Closed on Sept 29, 2025: gross proceeds of $4.0M from 2,666,667 shares at $1.50 and warrants.
Warrants for 2,666,667 shares at $1.37, immediately exercisable, 5-year term from resale registration.

Read filing →

February 6, 2026, 6:59 PM ET other material materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

Lexaria Bioscience receives Nasdaq bid price deficiency notice; 180 days to cure

Received Nasdaq deficiency notice on Feb 4, 2026 for failing to meet $1.00 min bid price (Rule 5550(a)(2)).
January 28, 2026, 6:59 PM ET other material materiality 0.05 neutral item 5.07

Lexaria Bioscience shareholders elect all director nominees, ratify auditors at annual meeting

All seven director nominees elected: highest vote % John Docherty (96.4%), lowest Albert Reese Jr. (73.6%).
December 16, 2025, 6:59 PM ET other materiality 0.55 neutral item 1.01 item 3.02 item 8.01 item 9.01

Lexaria raises $3.5M in registered direct offering with warrants

Issued 2,661,600 shares at $1.315/share, gross proceeds ~$3.5M.
September 29, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 8.01 item 9.01

Lexaria closes $4M registered direct offering of 2.67M shares at $1.50 with warrants at $1.37

Closed on Sept 29, 2025: gross proceeds of $4.0M from 2,666,667 shares at $1.50 and warrants.
September 25, 2025, 7:59 PM ET other material materiality 0.30 neutral item 1.02

Lexaria Bioscience terminates $5M equity distribution agreement with JonesTrading

Terminated Capital on Demand Sales Agreement with JonesTrading effective September 19, 2025.
June 12, 2025, 7:59 PM ET other material materiality 0.55 positive item 1.0

Lexaria expands GLP-1-H24-4 trial with 5th tirzepatide arm

Added 5th study arm investigating DehydraTECH-tirzepatide capsules in GLP1-H24-4 diabetes trial.
April 28, 2025, 7:59 PM ET other material materiality 0.50 neutral item 1.01 item 3.02 item 8.01 item 9.01

Lexaria raises $2M via registered direct offering of common stock and pre-funded warrants

Gross proceeds $2M from sale of 2M shares/pre-funded warrants at $1.00 per share to one institutional investor.
February 5, 2025, 6:59 PM ET other material materiality 0.55 neutral item 1.01 item 9.01

Lexaria reduces at-the-market equity facility from $20M to $5M

Amended Capital on Demand Sales Agreement with JonesTrading; maximum aggregate principal amount reduced to $5M from $20M.
January 15, 2025, 6:59 PM ET other material materiality 0.15 neutral item 5.07

Lexaria shareholders re-elect all directors; McKechnie gets 54% support, Baxter 62%

Annual meeting on Jan 14, 2025: 9,761,279 shares (55.93% of outstanding) represented.
January 3, 2025, 6:59 PM ET leadership materiality 0.35 neutral item 5.02

Lexaria Bioscience enters new exec agreement with President/CSO Docherty; base salary, 50% bonus, 15-mo severance

New agreement effective Jan 1, 2025, replaces prior 2022 pact; Docherty remains President and Chief Scientific Officer.
December 18, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.0

Lexaria Bioscience signs ~AUD$5.1M clinical study agreement with Novotech for GLP-1-H24-4 trial

Effective Dec 2, 2024: Novotech as CRO for DehydraTECH Cannabidiol + GLP-1 agonists in pre- and Type II Diabetes.
October 18, 2024, 7:59 PM ET other material materiality 0.25 neutral item 5.08

Lexaria Bioscience sets Jan 14, 2025 annual/special meeting; director nomination deadline Nov 25

Joint Annual and Special Meeting scheduled for January 14, 2025.
October 16, 2024, 7:59 PM ET other material materiality 0.55 neutral item 1.01 item 3.02 item 8.01 item 9.01

Lexaria raises $5M via registered direct offering and private placement of warrants

Gross proceeds of $5.0M from sale of 1,633,987 shares at $3.06/share plus 4,551,019 warrants exercisable at $3.06.
October 2, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change ×3

Lexaria Bioscience appoints Michael Shankman as CFO, effective Oct 1, 2024

Michael Shankman, CPA, replaces resigned CFO Nelson Cabatuan; CEO Richard Christopher had been interim principal financial officer.
September 5, 2024, 7:59 PM ET leadership materiality 0.75 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Lexaria appoints Richard Christopher as CEO; Bunka transitions to Chairman

Richard Christopher, 54, appointed CEO effective Aug 31, 2024; he also serves as interim CFO until new CFO is hired.
August 22, 2024, 7:59 PM ET other material materiality 0.50 neutral item 1.01 item 9.01

Lexaria Bioscience enters $20M at-the-market equity sales agreement with JonesTrading

Up to $20M of common stock may be sold from time to time through Agent JonesTrading as ATM offering.
July 17, 2024, 7:59 PM ET other material materiality 0.70 positive item 5.02 item 7.01 item 9.01 ◈ executive_change

Lexaria animal study interim results: DehydraTECH liraglutide and CBD show weight loss; CFO Cabatuan resigns

CFO Nelson Cabatuan resigned effective July 15; becomes Chief Strategic Financial Advisor; 150k unvested options expire, vested 50k options reduced to July 2026.
April 30, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 9.01 ◈ Material Agreements

Lexaria exercises warrants for ~$4.4M, issues new warrants with $4.75 strike

Existing investor exercises 2,917,032 warrants for ~$4.4M; gross proceeds ~$4.7M including new warrant consideration.
April 24, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×3

Lexaria Bioscience shareholders elect all six directors and ratify auditor at annual meeting

All six director nominees elected with 85-99% support: Bunka, Docherty, Baxter, McKechnie, Reese Jr., Turkel.
March 21, 2024, 7:59 PM ET other material materiality 0.50 negative item 1.0

Lexaria Bioscience amends Japanese license deal; lowers minimum fees, drops exclusivity

Original exclusive perpetual license with Premier becomes non-exclusive, ending Aug 31, 2025.
March 15, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change

Lexaria Bioscience appoints Nelson Cabatuan as CFO effective March 14, 2024

Nelson Cabatuan, age 46, replaces temporary outsourced CFO services from NOW CFO.
March 1, 2024, 6:59 PM ET other material materiality 0.75 positive item 8.01

Lexaria Bioscience receives FDA clearance for Phase 1b hypertension trial HYPER-H23-1

FDA issued 'Study May Proceed' letter on Feb 29, 2024, for Lexaria's Investigational New Drug application.
February 16, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 8.01 item 9.01 ◈ Material Agreements ×2

Lexaria raises $3.6M in registered direct offering and private placement

Gross proceeds of ~$3.6M from issuance of 1,558,443 shares at $2.31/share and pre-funded warrants at $2.3099.
January 30, 2024, 6:59 PM ET regulatory materiality 0.60 neutral item 8.01

Lexaria files IND with FDA for phase 1b hypertension trial of DehydraTECH-CBD

Submitted IND to FDA on Jan 29, 2024, for phase 1b trial HYPER-H23-1 in stage 1 or 2 hypertension.
January 24, 2024, 6:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Lexaria CEO provides 2024 outlook; GLP-1 pilot shows DehydraTECH semaglutide benefit; IND filing imminent

Stock recovered above $1, avoiding reverse split; October capital raise on less punitive terms.